S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression

Please use this identifier to cite or link to this item:
https://osnadocs.ub.uni-osnabrueck.de/handle/urn:nbn:de:gbv:700-2016111415145
Open Access logo originally created by the Public Library of Science (PLoS)
Title: S100B Serum Levels Predict Treatment Response in Patients with Melancholic Depression
Authors: Ambrée, Oliver
Bergink, Veerle
Grosse, Laura
Alferink, Judith
Drexhage, Hemmo A
Rothermundt, Matthias
Arolt, Volker
Birkenhäger, Tom K
Abstract: Background: There is an ongoing search for biomarkers in psychiatry, for example, as diagnostic tools or predictors of treatment response. The neurotrophic factor S100 calcium binding protein B (S100B) has been discussed as a possible predictor of antidepressant response in patients with major depression, but also as a possible biomarker of an acute depressive state. The aim of the present study was to study the association of serum S100B levels with antidepressant treatment response and depression severity in melancholically depressed inpatients. Methods: After a wash-out period of 1 week, 40 inpatients with melancholic depression were treated with either venlafaxine or imipramine. S100B levels and Hamilton Depression Rating Scale (HAM-D) scores were assessed at baseline, after 7 weeks of treatment, and after 6 months. Results: Patients with high S100B levels at baseline showed a markedly better treatment response defined as relative reduction in HAM-D scores than those with low baseline S100B levels after 7 weeks (P=.002) and 6 months (P=.003). In linear regression models, S100B was a significant predictor for treatment response at both time points. It is of interest to note that nonresponders were detected with a predictive value of 85% and a false negative rate of 7.5%. S100B levels were not associated with depression severity and did not change with clinical improvement. Conclusions: Low S100B levels predict nonresponse to venlafaxine and imipramine with high precision. Future studies have to show which treatments are effective in patients with low levels of S100B so that this biomarker will help to reduce patients’ burden of nonresponding to frequently used antidepressants.
Citations: International Journal of Neuropsychopharmacology, 19(3), 2015:pyv103.
URL: https://repositorium.ub.uni-osnabrueck.de/handle/urn:nbn:de:gbv:700-2016111415145
Subject Keywords: major depression; predictive biomarker; antidepressant response; treatment resistance; neurotrophic factor
Issue Date: 14-Nov-2016
License name: Namensnennung 3.0 Unported
License url: http://creativecommons.org/licenses/by/3.0/
Type of publication: Einzelbeitrag in einer wissenschaftlichen Zeitschrift [article]
Appears in Collections:FB05 - Hochschulschriften

Files in This Item:
File Description SizeFormat 
pyv103SupplementaryMaterial_correctedOA.docxSupplementary data313,44 kBMicrosoft Word XML
pyv103SupplementaryMaterial_correctedOA.docx
View/Open
pyv103.full.pdfArticle849,55 kBAdobe PDF
pyv103.full.pdf
Thumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons